Skip to main content
logo
Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.17168
+0.00258 (1.53%)
At close: Jul 24, 2026

Northwest Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.51.381.381.931.681.01
Revenue Growth
1.63%-0.29%-28.47%14.79%67.46%-22.15%
Gross Profit
-23.8-27.41-33.51-25.8-33.83-19.3
Operating Income
-53.5-59.91-66.51-55.51-67.18-52.7
Net Income
-45.27-61.48-85.19-64.37-105.03179.13
Earnings Per Share
-0.03-0.04-0.07-0.06-0.10-0.06
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1.793.042.182.136.9715.17
Total Debt
63.9964.8367.4445.5626.2537.94
Net Cash (Debt)
-62.21-61.79-65.27-43.43-19.29-22.77
Net Cash Growth
------
Net Cash Per Share
-0.04-0.04-0.05-0.04-0.02-0.02

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-47.85-44.76-57.02-53.64-52.78-38.3
Capital Expenditures
-1.54-1.5-1.01-3.44-2.9-6.02
Free Cash Flow
-49.39-46.27-58.03-57.07-55.68-44.31
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-3574.01%-4347.90%-4812.45%-2873.09%-3991.74%-5243.98%
Pretax Margin
-2967.60%-4404.86%-6062.08%-3240.11%-6240.76%17823.48%
Profit Margin
-3023.98%-4461.32%-6164.40%-3331.94%-6240.76%17823.48%
FCF Margin
-3299.53%-3357.55%-4199.06%-2954.14%-3308.20%-4409.35%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----3.70
PS Ratio
193.59260.08263.35425.38493.23660.04